Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
31 - 40 of 1016
- Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes(2023)
Authors: Séverine Vermeire, Marc Ferrante, Peter Bossuyt, Gert De Hertogh
- Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study(2023)
Authors: Séverine Vermeire
Pages: 976 - 989 - Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE(2023)
Authors: Séverine Vermeire
Pages: 874 - 887 - Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study(2023)
Authors: Zhigang Wang, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
Pages: 3188 - 3190 - Phage therapy for hidradenitis suppurativa: a unique challenge and possible opportunity for personalized treatment of a complex, inflammatory disease.(2023)
Authors: Lene Bens, Sabrina Green, Daan Jansen, Tom Hillary, Jelle Matthijnssens, João Guedelha Sabino, Séverine Vermeire, An Van Laethem, Jeroen Wagemans, Rob Lavigne
Pages: 1221 - 1229 - Community Types of the Human Gut Virome are Associated with Endoscopic Outcome in Ulcerative Colitis(2023)
Authors: Daan Jansen, Gwen Falony, Jeroen Raes, Séverine Vermeire, Jelle Matthijnssens
Pages: 1504 - 1513 - Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.(2023)
Authors: Debby Thomas, Séverine Vermeire
- Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.(2023)
Authors: Dahham Alsoud, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Bram Verstockt
Pages: 1 - 9 - Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease(2023)
Authors: Bram Verstockt, Séverine Vermeire
- Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies(2023)
Authors: Bram Verstockt, Marc Ferrante, Séverine Vermeire
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)